07.07.25 -- Why CDMOs Are Leaving Small Molecules Behind

Explore how to approach the transition of migrating from a vial to a syringe or cartridge, the necessary compatibility testing, and the stresses on the bulk product during formulation and filling.

Examine some of the more challenging aspects surrounding in-use testing for parenteral delivery, along with potential strategies to address these issues.

Discover how new strategies are driving innovation and transforming the future of biologics manufacturing, from enhanced productivity to improved therapeutic quality.

Bikash Chatterjee, President and Chief Science Officer, Pharmatech Associates, says sponsors and CDMOs have different business models and strengths, and that is a good thing to exploit.

Observe five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.

Radiofrequency identification (RFID)-based unit-level tracking solutions for prefilled syringes are poised to help pharma manufacturers address risks and costly bottlenecks related to the fill-finish process.

Consider insights tailored specifically for drug product researchers and manufacturers, offering key knowledge on extractables, leachables, and effective implementation strategies.

Witness a common phenomenon observed in lyophilized biologic drug products. These case studies examine critical factors that contribute to vial fogging and vial selection.

This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

Learn why many CDMOs cannot handle complex recombinant proteins, which often require a CLD process fully integrated with other CDMO components, including analytics and formulation development.

Our compact, efficient facility delivers rapid, cost-effective viral vector manufacturing and development services powered by deep industry expertise.

Review how our parallel development service works seamlessly with our existing antibody capabilities, helping to accelerate your ADC program and reach market faster.

Take a virtual tour of our advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.

Surrozen was keen to get started on process development and manufacturing and needed a CDMO with experience developing and producing bispecific antibodies and fusion proteins.

Investigate a fully automated sterile filtration system with built-in PUPSIT, enhanced product recovery, and configurable recipes designed to meet EU GMP Annex 1 contamination control requirements.